FDA grants Fast Track designation to Tubulis’ TUB-040 for ovarian cancer treatment

Patients with ovarian cancer often develop resistance to platinum-based therapy, leaving them with limited and unsatisfactory therapeutic options. Credit: Ewa Urban from Pixabay.